新的参议院法案将禁止米非司酮，根据古特马赫研究所的数据，2023年米非司酮用于63%的堕胎手术
作者：Preston Mizell，福克斯新闻
发布时间： 2026年3月11日 美国东部时间下午2:34
福克斯新闻独家： 密苏里州共和党参议员乔希·霍利将提出一项新法案，要求撤销广受欢迎的堕胎药米非司酮的FDA批准。该新法案是在霍利去年提出的拟议立法基础上制定的，去年的法案将禁止米非司酮，并允许女性起诉从中获利的制造商，霍利认为这种药物”本质上是危险的”。
《保护女性免受化学堕胎侵害法案》于周二在参议院提出，将禁止使用米非司酮终止妊娠。
“科学是明确的：这种化学堕胎药物对女性本质上是危险的，并且容易被滥用。然而，像丹科实验室这样的大公司却从中获利数十亿美元，”霍利在一份声明中告诉福克斯新闻数字版。”这就是为什么我要提出新法案，禁止使用米非司酮进行堕胎，并授权女性起诉其制造商。国会必须立即采取行动，保护女性的健康和安全。”
如果该法案通过，将撤销FDA对该药物的批准，并将用于堕胎的米非司酮分销归类为违反联邦法律。根据古特马赫研究所的数据，2023年米非司酮用于63%的美国堕胎手术。
反堕胎组织呼吁卫生与公众服务部和FDA暂停堕胎药批准，加强安全规定
密苏里州共和党参议员乔希·霍利周二提出新立法，将在全国范围内禁止堕胎药米非司酮，称其为”本质上危险的”药物，并寻求撤销其FDA批准。(Michael M. Santiago/Getty Images)
与计划生育协会有联系的非营利研究机构古特马赫研究所还估计，2024年有1,038,100例由临床医生实施的堕胎手术。然而，这一数字仅统计了没有堕胎禁令的州，不包括在正规医疗系统外进行的堕胎，也不包括堕胎法律不同的州的情况。
霍利去年5月对堕胎药提出担忧，当时他提出了另一项法案，要求FDA对米非司酮建立安全保障措施，允许在遭受并发症的女性有权起诉远程医疗服务提供者和药房要求赔偿。
密苏里州共和党参议员乔希·霍利引用了伦理与公共政策中心的研究，称米非司酮的并发症发生率高于FDA批准标签上列出的数字。(Charlie Neibergall/AP)
华盛顿特区伦理与公共政策中心(EPPC)的研究显示，使用米非司酮的副作用发生率是FDA批准的药品标签上显示的22倍。
反堕胎组织敦促参议院就堕胎药安全问题向肯尼迪·罗纳德·费尔南德斯追问，要求恢复安全保障措施
研究显示，超过十分之一的女性报告经历过”感染、出血或其他严重或危及生命的不良事件”。
EPPC评估了2017年至2023年间865,727份女性使用该药物终止早孕的保险索赔。根据FDA的数据，该药物可在”自末次月经第一天起70天内”服用。
在拜登政府期间，FDA修订了规定，允许通过远程医疗开具米非司酮处方，这意味着患者无需亲自前往诊所即可获得堕胎药物。
南卡罗来纳州共和党议员提出将堕胎定为谋杀罪的法案
2024年，最高法院一致驳回了希波克拉底医学联盟提出的旨在推翻FDA对该药物批准和扩大获取范围的诉讼。该裁决允许米非司酮继续通过远程医疗和邮寄方式提供。
霍利致函FDA专员马蒂·马卡利，敦促他重新审查数据并对堕胎药米非司酮采取行动。(Andrew Harnik/Getty Images)
最高法院的驳回是基于该组织无法提起诉讼，称希波克拉底医学联盟缺乏质疑FDA批准的法律资格。该堕胎药物的是非曲直从未在裁决中被讨论或质疑。
去年5月，霍利致函FDA专员马卡利，而霍利在去年马卡利的参议院确认听证会上对他进行了质询。
点击此处下载福克斯新闻应用
“在你的确认听证会上，你向我保证你会’审查全部数据和持续更新的数据’，以便对该药物采取行动，”霍利致函FDA负责人的信中说。”我敦促你关注这些新数据，并采取一切适当行动，恢复对米非司酮使用的关键安全保障措施。
“美国女性的健康和安全取决于这些行动。”
Preston Mizell是福克斯新闻的撰稿人。新闻线索可发送至Preston.Mizell@fox.com，或在X平台@MizellPreston联系他
Preston Mizell是福克斯新闻数字版报道突发新闻的撰稿人。
Hawley introduces bill to strip FDA approval from ‘inherently dangerous’ abortion pill
New Senate bill would prohibit mifepristone, which was used in 63% of all abortions in 2023, according to Guttmacher Institute data
By Preston MizellFox News
Published March 11, 2026 2:34pm EDT
FIRST ON FOX: Sen. Josh Hawley, R-Mo., is introducing a new bill to strip FDA approval from the popular abortion pill mifepristone. The new bill builds upon proposed legislation Hawley introduced last year that would ban mifepristone and allow women to sue manufacturers profiting off of what the lawmaker deems an “inherently dangerous” drug.
The Safeguarding Women from Chemical Abortion Act was introduced in the Senate Tuesday and would prohibit the use of mifepristone for ending pregnancies.
“The science is clear: The chemical abortion drug is inherently dangerous to women and prone to abuse. Yet major companies like Danco Laboratories are making billions off it,” Hawley told Fox News Digital in a statement. “That’s why I am introducing new legislation to ban the use of mifepristone for abortion and empower women to sue its manufacturers. Congress must act now to protect the health and safety of women.”
If passed, the legislation would withdraw FDA approval for the drug and classify its distribution for abortion as a violation of federal law. In 2023, mifepristone was used in 63% of all abortions in the U.S., according to data from the Guttmacher Institute.
PRO-LIFE ORGANIZATION CALLS ON HHS AND FDA TO SUSPEND ABORTION PILL APPROVAL, TIGHTEN SAFETY RULES
Sen. Josh Hawley, R-Mo., introduced new legislation Tuesday that would ban the abortion pill mifepristone nationwide, calling it an “inherently dangerous” drug and seeking to revoke its FDA approval.(Michael M. Santiago/Getty Images)
The Guttmacher Institute, a nonprofit research organization formerly affiliated with Planned Parenthood, also estimates there were 1,038,100 clinician-provided abortions in 2024. However, that figure accounts only for states without abortion bans and does not include abortions performed outside the formal healthcare system or in states where abortion laws differ.
Hawley raised concerns about the abortion pill last May when he introduced a separate bill that would direct the FDA to create safeguards on mifepristone, allowing women who suffered complications the right to sue telehealth providers and pharmacies for damages.
Sen. Josh Hawley, R-Mo., cited research from the Ethics and Public Policy Center claiming higher rates of complications from mifepristone than listed on the FDA-approved label.(Charlie Neibergall/AP)
Research by the Ethics and Public Policy Center (EPPC) in Washington, D.C., showed the rate of side effects when using mifepristone is 22 times higher than indications from the FDA-approved drug label.
PRO-LIFE GROUP URGES SENATE TO PRESS RFK JR. ON ABORTION PILL SAFETY, DEMAND SAFEGUARDS RETURN
The study revealed more than 1 in 10 women have reported experiencing “infection, hemorrhaging, or another serious or life-threatening adverse event.”
EPPC assessed 865,727 insurance claims between 2017 and 2023 for women who used the medication to terminate early pregnancy. The pill can be taken up to “70 days since the first day of their last menstrual period,” according to the FDA.
During the Biden administration, the FDA revised rules allowing mifepristone to be prescribed via telehealth, meaning patients would not have to physically go to the doctor to receive the abortion drug.
SOUTH CAROLINA GOP LAWMAKERS INTRODUCE BILL TO CRIMINALIZE ABORTION AS MURDER
In 2024, the Supreme Court unanimously rejected an Alliance for Hippocratic Medicine challenge that was brought to reverse the FDA’s approval and expansion for access to the drug. The ruling allowed mifepristone to remain available through telehealth and mail.
Hawley penned a letter to FDA Commissioner Marty Makary urging him to review the data and act against the abortion drug mifepristone.(Andrew Harnik/Getty Images)
The Supreme Court’s rejection was based on the group’s inability to bring a lawsuit, saying Alliance for Hippocratic Medicine lacked the legal standing to challenge FDA approval. The merits of the abortion drug were never discussed or questioned in the ruling.
Last May, Hawley sent a letter to FDA Commissioner Marty Makary, whom Hawley questioned during Makary’s Senate confirmation hearing last year.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“[D]uring your confirmation hearing, you pledged to me that you would ‘review the totality of the data and ongoing data’ to inform action on the drug,” Hawley’s letter to the FDA chief states. “I urge you to follow this new data and take all appropriate action to restore critical safeguards on the use of mifepristone.
“The health and safety of American women depend on it.”
Preston Mizell is a writer with Fox News. Story tips can be sent to Preston.Mizell@fox.com and on X @MizellPreston
Preston Mizell is a writer with Fox News Digital covering breaking news.
发表回复